Weekly updates on new data, current advances, and best practices in patient care for a variety of medical specialties including NASH, diabetes, muscular dystrophy, and more from Clinical Care Options. Gain practical strategies and earn CME/CE credit for selected episodes.
every other week
infrequent
every other week
every other week
Listen as Michael S. Blaiss, MD provides case-based perspectives on chronic cough recognition, burden, management, and pathophysiology and describes the evolving treatment landscape for refractory chronic cough.PresenterMichael S. Blaiss, MDClinical Professor of PediatricsDivision of Allergy-ImmunologyMedical College of Georgia at Augusta UniversityAugusta, GeorgiaLink to full program: https://bit.ly/4kweynG
Listen in as Paula Henao, MD; Rohit Loomba, MD, MHSc; Cheryl Pirozzi, MD, MS; and Corinne Young, NP, FCCP, discuss their screening and monitoring strategies for patients with alpha-1 antitrypsin deficiency, including:Why early detection is key for improving patient outcomesHow to monitor through use of noninvasive imaging and biopsy per guideline recommendationsHow to coordinate patient care to provide much-needed multidisciplinary careWhat therapies in the pipeline could transform the treatment landscape for this genetic disease PresentersPaula Henao, MDAssistant Professor of MedicineDivision of Pulmonary, Allergy and Critical Care MedicinePenn State Hershey Medical CenterHershey, PennsylvaniaRohit Loomba, MD, MHScProfessor of MedicineChief, Division of Gastroenterology and HepatologyDirector, MASLD Research CenterUniversity of California, San DiegoSan Diego, CaliforniaCheryl Pirozzi, MD, MSAssociate Professor of Internal MedicineDivision of Pulmonary and Critical Care MedicineUniversity of UtahSalt Lake City, UtahCorinne Young, NP, FCCPPresident/FounderAssociation of Pulmonary Advanced Practice ProvidersColorado Springs, ColoradoLink to full program: https://bit.ly/4dgCRnq
Listen in as Joseph Kim, MD, MPH, MBA, interviews Sejal Desai, MD, DABOM, to learn about how she implemented virtual support groups to improve obesity care at her practice, including:Dedicating 5 support groups with chat features to obesity-specific topics (eg, sleep, nonscale wins)Moderating these chats to ensure no misinformation is shared and a positive, safe space is maintainedExpanding to include other virtual options that allow patients to engage more in their careUtilizing free and subscription-based services to aid in marketing effortsSharing lessons learned for those interested in implementing similar virtual options for their patients PresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaSejal Desai, MD, DABOMBoard-Certified Obesity Medicine PhysicianOwner & Medical DirectorTula Medical Weight Loss & WellnessKaty, TexasLink to full program: https://clinicaloptions.com/content/qi-resource-hub
Listen in as Joseph Kim, MD, MPH, MBA, interviews Sophia Kwon, MD, to learn about how she implemented a documentation shortcut at her institution to improve obesity care, including:Creating an obesity checklist within the electronic health recordTraining staff to correctly use this checklist and broach obesity topics with patientsGarnering feedback to ensure this checklist did not add to note fatigue or burnout among staffSharing lessons learned for others interested in implementing a similar documentation shortcutPresenterJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, Pennsylvania Sophia Kwon, MDInternal Medicine AttendingRiverside University Health System AttendingLoma Linda University Health Associate FacultyLoma Linda, California
In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the program Hear Me: Patient Perspectives on PBC
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include: How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelparPotential outcomes if ALP normalization cannot be achievedThe importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical responsePresenters:Stuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:The chronic nature of PBCGoing beyond biochemical markers to assess and address symptoms such as fatigue and pruritusThe importance of referral to patient support groupsPresenters:Sonal Kumar, MD, MPHAssistant Professor of MedicineDirector, General Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkMaria G. Morais, RNVP Patient AdvocacyCanadian PBC SocietyToronto, CanadaTo learn more, see the program Hear Me: Patient Perspectives on PBC
Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program:https://bit.ly/4gkTzSv
In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:ELATIVE, a phase III trial of elafibranor for PBCRESPONSE, a phase III trial of seladelpar for PBCASSURE, another phase III trial of seladelpar for PBCPresenter:Sonal Kumar, MD, MPHDirector, Clinical Gastroenterology and HepatologyAssistant Professor of MedicineWeill Cornell Medical CollegeNew York, New YorkLink to full program:https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients' quality of life.Listen as they discuss:Gaps in current managementPatient perspectives: why we should not dismiss itching as an underlying psychologic problemPPAR agonists and how they affect pruritusBEZURSO and FITCH ELATIVEENHANCE and RESPONSEIBATs (inhibitors of bile acid transport)GLIMMERCommon questionsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E
Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:Pruritus assessment toolsOptimal use of tools, including frequency of assessmentCurrent management of pruritusNonpharmacologic interventionsPharmacologic agentsStrategies to optimize assessment and management of pruritusCollaborative careDevelopment of a treatment planOngoing assessment and adjustment of therapyResources and support for patientsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E
In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient's perspective. Presenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBC Link to full program: https://bit.ly/4gDGDaB
In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:Treatment goalsUse of PPAR agonists for the treatment of PBCClinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)Presenter:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologyUniversity of California Davis School of MedicineSacramento, CaliforniaLink to full program: https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Listen as Elizabeth Kircher, DNP, and R. Hal Scofield, MD, discuss best practice approaches for the treatment of Sjögren's syndrome and what's on the horizon for future therapeutic options.Topics include:Challenges in Sjogren's Syndrome Diagnosis and Patient Understanding: Difficulties in explaining Sjogren's syndrome diagnosis to patients unfamiliar with it and challenges in addressing the disease's varied symptomsPatient Education and Communication: Strategies to prevent overwhelming patients during early visits and effective ways to address misconceptionsDiagnostic Challenges and Misunderstandings: Differences between clinical and research criteria for diagnosis and the importance of understanding eachUse of Ultrasound and Biopsy in Diagnosis: Benefits and limitations of ultrasound and biopsies in diagnosing Sjogren's syndromeMultidisciplinary Care Barriers: Challenges in coordinating care among specialists such as ophthalmologists, dentists, and rheumatologistsSymptomatic vs Disease-Modifying Treatments: Strategies for managing symptoms vs addressing the underlying disease with medicationsLong-term Medication and Risks: Considerations when prescribing long-term medications and immunosuppressive therapiesResearch and Emerging Therapies: Developments in Sjogren's syndrome research, including promising medications in clinical trialsGuideline Development and Patient Reassurance: The role of professional guidelines in shaping care and providing patients with reassurancePolypharmacy and Medication Reconciliation: The importance of pharmacist involvement in managing complex medication regimens for older patients Faculty:Elizabeth Kircher, DNPR. Hal Scofield, MDMember/Professor, Arthritis & Clinical ImmunologyOklahoma Medical Research FoundationProfessor, Department of Medicine, College of MedicineUniversity of Oklahoma Health Sciences CenterAssociate Chief of Staff for ResearchOklahoma City US Department of Veterans Affairs Medical CenterOklahoma City, OklahomaLink to full program:https://bit.ly/3YKpsOE
In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients' kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies. Topics include:Supportive care as the foundation of IgAN managementPlace in therapy for new and emerging agentsTargeted-release formulation of budesonideEndothelin receptor antagonists (eg, sparsentan)Factor B inhibitors (eg, iptacopan)The role of clinical trial involvementLearn more about IgA nephropathy with educational activities and resources here: CME-certified text module with animated pathophysiology video and patient voice audio clipClinicalThought commentariesResources on IgAN from the American Kidney Fund
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD. Episode outline: Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD. Episode outline: The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD. Episode outline: Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD
In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases. Episode outline: Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyondTo learn more about IgA nephropathy, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At
In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability Presenters:Jennifer Green, MDProfessor of MedicineDivision of Endocrinology and Duke Clinical Research InstituteDuke University School of MedicineDurham, North CarolinaCarol Hatch Wysham, MDClinical Professor of MedicineClinical EndocrinologistMultiCare/Rockwood ClinicSpokane, WashingtonLink to online program: https://bit.ly/48b6XnW
In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z
In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Marla Dubinsky, MD, discuss how women in gastroenterology (GI) can find their “friendtors” and build a strong network of mentors, sponsors, and allies. Although there may be many barriers for women in the GI medicine specialty, these experienced leaders have useful tips to help emerging healthcare professionals avoid internalizing these challenges and strategically focus on accomplishing their goals. Presenters: Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels. Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.Dr Marla Dubinsky is a Professor of Pediatrics and Medicine at Mount Sinai in New York, Chief of Division of Pediatric GI and Nutrition at Mount Sinai Kravis Children's Hospital, and the Co-Director of the Susan and Leonard Feinstein IBD Clinical Centre. Dr Dubinsky is also the Director of the Marie and Barry Lipman IBD Preconception and Pregnancy Clinic. She is also an innovator and the Co-Founder of Trellus Health, providing personalized resilience coaching for people living with IBD. She received the Sherman Prize in 2022, which recognized her outstanding achievement in the field of IBD. In addition, she served as the Co-Chair for our inaugural Scrubs & Heels Leadership Summit in 2022. Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Takeda.Episode outline: Overview of barriers faced by women in GIImpact of failing to adequately address these barriersDefining the roles of mentors, sponsors, and alliesImportant qualities of mentors, sponsors, and alliesRole models vs peer mentorsOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and DevelopmentPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GIAfter selecting the “Continue to Post Test” button:To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom
In this podcast episode, Anita Afzali, MD, MPH, MHCM, FACG, AGAF, and Aja McCutchen, MD, discuss how women in gastroenterology (GI) can embrace and enhance their value. These inspiring GI medicine experts propose a practical formula that involves ongoing, careful self-reflection and asking yourself how your strengths, core values, and interests can be aligned with professional endeavors. In addition, self-advocacy and self-allyship can serve as harmonious tools to drive action and positive change. Presenters:Dr Anita Afzali is a Professor of Clinical Medicine, Interim Division Director of the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine, and the Associate Chief Medical Officer of the UC Health system in Cincinnati, Ohio. She is also a Co-Founder of Scrubs & Heels.Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant: AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Lilly, Pfizer, Takeda; provider of non-CME/CE services: AbbVie, Janssen, Pfizer, Takeda.Dr Aja McCutchen is a Partner and Physician Executive at Atlanta Gastroenterology Associates, a division of United Digestive in Atlanta, Georgia, and served as Co-Chair at the Scrubs & Heels 2023 Leadership Summit. Aja McCutchen, MD: consultant/advisor/speaker: Eli Lilly, Modify Health, Redhill Biopharm, Sanofi Regeneron, Takeda.Episode outline: Understanding and establishing your own market value; bringing that to your own organizationConsequences of being ill-equipped to pursue professional growth and developmentAdvocating for the value you bring to the professionNegotiation as a form of self-allyshipNegotiation categories to help support career success and protect work–life balanceOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 1: Finding Your Friendtors: Mentors, Sponsors, and AlliesPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GITo receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.
In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Christina Tennyson, MD, DipABLM, discuss how women in gastroenterology (GI) can fight burnout and establish a work–life balance that meets their needs. Tune in to learn how to say no, about the importance of saying yes to meaningful things that will advance your career and bring you joy, and get essential tips for well-rounded and ongoing self-care. Presenters:Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels. Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.Dr Christina Tennyson is a gastroenterologist with expertise and certification in nutrition, lifestyle medicine, and integrative medicine. She started her career in academia at Columbia University in New York before joining the Augusta Health Digestive Wellness program in the Virginia Shenandoah Valley, where she is engaged in a multidisciplinary program that includes culinary medicine classes and farm workshops for patients. Christina Tennyson, MD, DipABLM, has no relevant financial relationships to disclose.[Link to: https://scrubsandheels.com/] Episode outline: Variables that contribute to burnoutStrategies to protect your timeVetting collaborative projectsRequesting flexible schedules, part-time work, maternity leaveCharting your own career pathPrioritizing personal timePreserving friendships, hobbiesLeave work at workOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GI https://bit.ly/3Zmqy1I]Podcast 1: Finding Your Friendtors: Mentors, Sponsors, and Allies https://bit.ly/3LuKzO6Podcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and Development https://bit.ly/3RsFl9iClinicalThought: Expert Commentary on Thriving as Women in GI https://bit.ly/48oi5iSLink to CME: Claim Credit: https://bit.ly/48oi5iS[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.
This podcast episode is part of a multimedia program discussing the impact of health disparities in anemia of chronic kidney disease (CKD) on patient outcomes. Tune in to hear Santosh Saraf, MD, and Milda Saunders, MD, MPH, highlight mitigation strategies to improve screening and management. The overview will include: The definition of CKD and the relative prevalence in specific minority groupsHow health disparities affect CKD-related clinical and patient outcomesAppropriate screening techniques to diagnose patients with anemia of CKDStrategies to address health disparities to improve patient outcomes in the management of anemia of CKDPresenters: Santosh Saraf, MDAssociate Professor of MedicineDivision of Hematology and OncologyDepartment of MedicineUniversity of Illinois at ChicagoChicago, Illinois Milda Saunders, MD, MPHAssociate Professor of MedicineDepartment of MedicineUniversity of ChicagoChicago, IllinoisTo view other program offerings, including a CE-certified on-demand webcast, a ClinicalThought commentary, and to download slides, visit:https://bit.ly/3iL07S0
In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.Presenters: Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioReview the downloadable slidesets at: https://bit.ly/3mlHOlaLink to full program:https://bit.ly/3aC2NNL
In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHAProfessor of Medicine Tulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program:https://bit.ly/3MbIfZI
In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program: https://bit.ly/3MbIfZI
In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include: Disproportionate prevalence among marginalized groups in the United StatesLupus-related social determinants of healthChallenges with medication adherenceStrategies to reduce these disparitiesPresenters:Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioThis episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link: https://bit.ly/3PWAzNU
This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and the full program at: https://bit.ly/3yYXP8e
This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF.Review the downloadable slideset and the full program at: https://bit.ly/3yYXP8e
This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study.Review the downloadable slideset and the full program at:https://bit.ly/3yYXP8e
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series inbDMARD-IRMTX-IRMTX naiveAlso included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cyclingPresenters:Stanley B. Cohen, MDClinical ProfessorDepartment of Internal MedicineUniversity of Texas Southwestern Medical SchoolCo-DirectorDivision of RheumatologyPresbyterian HospitalCo-Medical DirectorMetroplex Clinical Research CenterDallas, Texas Sheetal Desai, MD, MSEdChief of RheumatologyProgram DirectorUniversity of California, IrvineIrvine, CaliforniaEric M. Ruderman, MDProfessor, Associate ChiefDivision of RheumatologyNorthwestern University Feinberg School of MedicineClinical Practice DirectorNorthwestern Medical GroupChicago, IllinoisDownload the accompanying slides at:https://bit.ly/37bm6cJSee the interactive video at:https://bit.ly/3oCOtpV
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss the recent changes in rheumatoid arthritis treatment options, reviewing the landscape of targeted DMARDs and JAK inhibitors, including:Kinase signalingJAK inhibitor activity and signalingJAK selectivityPresenters:Stanley B. Cohen, MDClinical Professor Department of Internal MedicineUniversity of Texas Southwestern Medical SchoolCo-DirectorDivision of RheumatologyPresbyterian HospitalCo-Medical DirectorMetroplex Clinical Research CenterDallas, Texas Sheetal Desai, MD, MSEdChief of RheumatologyProgram DirectorUniversity of California, IrvineIrvine, CaliforniaEric M. Ruderman, MDProfessor, Associate ChiefDivision of RheumatologyNorthwestern University Feinberg School of MedicineClinical Practice DirectorNorthwestern Medical GroupChicago, IllinoisDownload the accompanying slides at:https://bit.ly/3447GceSee the interactive video at:https://bit.ly/3oCOtpV
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss how to translate information on JAK inhibitors and other treatments for your patient population in the clinic, covering practical tips on using:Treat-to-target approachesDisease activity measuresShared decision-makingDecision aidsTranslating clinical trial evidenceAlso included are the experts’ answers to questions from clinicians like you.Stanley B. Cohen, MDClinical ProfessorDepartment of Internal MedicineUniversity of Texas Southwestern Medical SchoolCo-DirectorDivision of RheumatologyPresbyterian HospitalCo-Medical DirectorMetroplex Clinical Research CenterDallas, Texas Sheetal Desai, MD, MSEdChief of RheumatologyProgram DirectorUniversity of California, IrvineIrvine, CaliforniaEric M. Ruderman, MDProfessor, Associate ChiefDivision of RheumatologyNorthwestern University Feinberg School of MedicineClinical Practice DirectorNorthwestern Medical GroupChicago, IllinoisDownload the accompanying slides at:https://bit.ly/3gHDE3sSee the interactive video at:https://bit.ly/3oCOtpV
What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.Download the slides from this podcast at:https://bit.ly/3gpzuMjSee more NASH topics at:https://bit.ly/3ezkBq6
Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including:Should We Screen for NASH?Role of obesity and type 2 diabetes mellitusCardiovascular Risk in NAFLD/NASHHow to Evaluate for NAFLD/NASHBiomarkersImagingWhen/whom to biopsy?Management in Multidisciplinary SettingsDownload the slides from this podcast at:https://bit.ly/2ZBvVvySee more NASH topics at:https://bit.ly/3ezkBq6
Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:• Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2• Assessment of therapeutic response• Assessment of long-term patient outcomesDownload the slides from this podcast at:https://bit.ly/3il5rqGSee more NASH topics at: https://bit.ly/3ezkBq6
Hear Philip N. Newsome, PhD, FRCPE, discussavailable approaches to managing NASH, including lifestyle, vitamin E, and compounds that target insulin resistance, including:Recommended Pharmacologic Therapies for NASHPioglitazoneVitamin EOptimal Diabetes Therapies in NAFLD/NASHWeight LossLiver HealthSurgical Approaches to Weight Loss and Effect on LiverDownload the slides from this podcast at:https://bit.ly/3ig0r6xSee more NASH topics at:https://bit.ly/3ezkBq6
Hear Dr. Katherine Wagner *and *Dr. Richard Finkle discussnovel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored.Download the slides from this podcast at: https://bit.ly/2zZgB2XSee more neurology topics at:https://bit.ly/3eAMVby
Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:Obeticholic acidCenicrivirocResmetiromAramcholDownload the slides from this podcast at:https://bit.ly/3eJYKvWSee more NASH topics at: https://bit.ly/3ezkBq6
Link to CME: Claim Credit - https://bit.ly/3dQPQwT .Continuous glucose monitoring (CGM) is a great tool that improves clinical outcomes for people with diabetes; these individuals are often happy to get this new technology.However, there can be some initial barriers that both people with diabetes and clinicians need to overcome.BARRIER 1: Wearing something on the body so other people know the person has diabetes.SOLUTION 1: Let the person see the size of different devices through demonstrations and show possible discreet places on the body where they can be worn.Consider starting with a professional CGM, owned by the clinic and borrowed by the individual for up to 14 days, so that he or she can get a feel for what it is like.Consider a CGM that can be integrated with a smart pen instead of an insulin pump, so the individual has only 1 device to wear.BARRIER 2: Cost of the CGM.SOLUTION 2: Find out insurance requirements to see if the CGM can be covered and what is required for coverage.A disposable sensor is a lower cost option. There are coupons available and some pharmacies sell for lower costs.Professional CGM is an underused insurance benefit that is often covered multiple times per year if used on a short- term basis.BARRIER 3: Too much information from CGM can be overwhelming for the individual.SOLUTION 3: Make sure alarms and alerts are set appropriately to avoid alarm fatigue—have the alerts go off when it matters most, like during hypoglycemia. Look at the device at key times only, like before meals, before bedtime, and before activities like exercising and driving, and utilize CGM to determine glycemic trends.BARRIER 4: Clinicians are hesitant to embrace CGM technology.SOLUTION 4: There are various resources available to help clinicians understand CGM technology and to assist in integrating CGM into their practice settings.Online tutorials, industry representatives, and diabetes care and education specialists can help clinicians understand how to start people with diabetes on CGM and how to interpret the data.CPT codes are now available to help support the cost of additional staff to train the individual on the devices and cover the cost of review and interpretation.Presenters:Carla Cox PhD, RD, FAADECertified Diabetes Educator and Clinical DietitianMountain Vista Medicine South Jordan, UtahDiana Isaacs PharmD, BCPS, BCACP, BC-ADM, CDEClinical Pharmacy Specialist/CGM Program CoordinatorDepartment of Endocrinology, Diabetes, and MetabolismCleveland Clinic Diabetes CenterCleveland, OhioProvided by the Endocrine Society in collaboration with the ADCES.Supported by an educational grant from Lilly.
© 2020-2025 Ivy Podcast Discovery LLC
